Savant Capital LLC Has $8.58 Million Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Savant Capital LLC grew its position in DexCom, Inc. (NASDAQ:DXCM) by 9.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 110,383 shares of the medical device company’s stock after purchasing an additional 9,731 shares during the period. Savant Capital LLC’s holdings in DexCom were worth $8,584,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in DXCM. Crossmark Global Holdings Inc. raised its holdings in shares of DexCom by 1.0% in the third quarter. Crossmark Global Holdings Inc. now owns 18,778 shares of the medical device company’s stock valued at $1,259,000 after buying an additional 182 shares during the last quarter. GPS Wealth Strategies Group LLC raised its holdings in shares of DexCom by 13.2% in the fourth quarter. GPS Wealth Strategies Group LLC now owns 1,587 shares of the medical device company’s stock valued at $123,000 after buying an additional 185 shares during the last quarter. Magnolia Capital Advisors LLC raised its holdings in shares of DexCom by 2.6% in the fourth quarter. Magnolia Capital Advisors LLC now owns 8,198 shares of the medical device company’s stock valued at $638,000 after buying an additional 210 shares during the last quarter. Riverview Trust Co raised its holdings in shares of DexCom by 100.4% in the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after buying an additional 232 shares during the last quarter. Finally, MassMutual Private Wealth & Trust FSB raised its holdings in shares of DexCom by 46.7% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company’s stock valued at $65,000 after buying an additional 265 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insider Transactions at DexCom

In other news, EVP Jereme M. Sylvain sold 2,090 shares of the company’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $181,641.90. Following the sale, the executive vice president now owns 83,526 shares in the company, valued at $7,259,244.66. This represents a 2.44 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Sadie Stern sold 4,259 shares of the company’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the sale, the executive vice president now owns 71,192 shares in the company, valued at approximately $5,320,178.16. This represents a 5.64 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 42,342 shares of company stock worth $3,628,069 in the last 90 days. Corporate insiders own 0.30% of the company’s stock.

DexCom Trading Up 0.2 %

NASDAQ:DXCM opened at $88.27 on Tuesday. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. The business has a 50 day moving average price of $81.76 and a two-hundred day moving average price of $75.11. The company has a market cap of $34.48 billion, a P/E ratio of 52.86, a price-to-earnings-growth ratio of 2.26 and a beta of 1.14.

Analyst Ratings Changes

DXCM has been the subject of a number of research analyst reports. Redburn Atlantic raised DexCom from a “neutral” rating to a “buy” rating and lifted their price target for the company from $85.00 to $115.00 in a report on Monday, February 3rd. JPMorgan Chase & Co. boosted their price objective on DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a report on Friday, October 25th. Canaccord Genuity Group boosted their price objective on DexCom from $89.00 to $99.00 and gave the stock a “buy” rating in a report on Monday, December 9th. Wells Fargo & Company boosted their price objective on DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. Finally, Baird R W raised DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Four research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, DexCom has a consensus rating of “Moderate Buy” and a consensus price target of $98.41.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.